Trials / Completed
CompletedNCT03541616
Prevalence of Subclinical Atrial Fibrillation in Heart Failure Patients and Its Relationship With Hospital Readmission
Prevalence of Subclinical Atrial Fibrillation in High Risk Heart Failure Patients and Its Temporal Relationship With Hospital Readmission for Heart Failure
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 242 (actual)
- Sponsor
- Population Health Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicentre, prospective cohort study in patients with a history of HF with preserved or reduced ejection fraction admitted to hospital with acutely decompensated HF. Eligible and consenting patients will be enrolled at 3 Hamilton, Ontario area hospitals and receive 28-day ECG monitoring implemented at the time of hospital discharge. Patients will be followed for a total of 1 year from hospital discharge.
Detailed description
In patients discharged from hospital after an admission for acute heart failure (HF) decompensation, subclinical atrial fibrillation (AF) of 30 minutes or greater in duration is common (at least 15% of patients without prior AF) and is associated with increased risk of re-hospitalization within 30-days. Study Objectives: 1. To evaluate the prevalence of subclinical AF ≥30 minutes in duration in patients discharged from hospital following an admission for acute HF exacerbation and who have no known history of clinical AF. 2. To examine the temporal association between subclinical AF ≥30 minutes in duration and 30-day hospital readmission for HF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ECG Patch, pocket ECG monitor | Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge . |
Timeline
- Start date
- 2018-03-24
- Primary completion
- 2022-01-31
- Completion
- 2023-03-27
- First posted
- 2018-05-30
- Last updated
- 2023-03-31
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03541616. Inclusion in this directory is not an endorsement.